Workflow
Perspective Therapeutics(CATX)
icon
Search documents
Perspective Therapeutics(CATX) - 2021 Q1 - Earnings Call Transcript
2020-11-11 00:29
IsoRay, Inc. (ISR) Q1 2021 Earnings Conference Call November 10, 2020 4:30 PM ET Company Participants Mark Levin - Investor Relations Lori Woods - Chief Executive Officer Jonathan Hunt - Chief Financial Officer Conference Call Participants Operator Greetings and welcome to the Isoray First Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this confer ...
Perspective Therapeutics(CATX) - 2020 Q4 - Annual Report
2020-09-24 22:31
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File No. 001-33407 Isoray, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |---------------- ...
Perspective Therapeutics(CATX) - 2020 Q4 - Earnings Call Transcript
2020-09-17 22:49
IsoRay, Inc. (ISR) Q4 2020 Results Conference Call September 17, 2020 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Ed Woo - Ascendiant Capital Swayampakula Ramakanth - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to IsoRay Fourth Quarter 2020 Earnings Conference Call. All lines have been placed on a listen-only mode and the floor will be open for your questions and comments following the presentation. [Operator In ...
Perspective Therapeutics(CATX) - 2020 Q3 - Quarterly Report
2020-05-13 12:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File No. 001-33407 ISORAY, INC. (Exact name of registrant as specified in its charter) Delaware 41-1458152 (State ...
Perspective Therapeutics(CATX) - 2020 Q3 - Earnings Call Transcript
2020-05-13 01:06
IsoRay, Inc. (ISR) Q3 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Jason Kolbert - Dawson James Ed Woo - Ascendiant Capital William Urschel - Accord Partners Operator Good day, ladies and gentlemen, and welcome to your IsoRay Inc. Third Quarter 2020 Earnings Conference Call. All lines have been placed in a listen-only mode and the floor will be open for your questions and comments following the pr ...
Perspective Therapeutics(CATX) - 2020 Q2 - Quarterly Report
2020-02-12 13:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File No. 001-33407 ISORAY, INC. (Exact name of registrant as specified in its charter) Delaware 41-1458152 (St ...
Perspective Therapeutics(CATX) - 2020 Q2 - Earnings Call Transcript
2020-02-12 04:07
IsoRay, Inc. (ISR) Q2 2020 Results Earnings Conference Call February 11, 2020 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Jason Kolbert - Dawson James Ed Woo - Ascendiant Capital Swayampakula Ramakanth - H.C. Wainwright William Urschel - Accord Partners Operator Good day, ladies and gentlemen, and welcome to your IsoRay Inc. Second Quarter Fiscal Year 2020 Call. All lines have been placed in a listen-only mode and the floor will be open f ...
Perspective Therapeutics(CATX) - 2020 Q1 - Quarterly Report
2019-11-13 21:35
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File No. 001-33407 ISORAY, INC. (Exact name of registrant as specified in its charter) Delaware 41-1458152 (S ...
Perspective Therapeutics(CATX) - 2020 Q1 - Earnings Call Transcript
2019-11-12 23:47
IsoRay, Inc. (ISR) Q1 2020 Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - Co-Principal Financial Officer Conference Call Participants Ed Woo - Ascendiant Capital Arthur He - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the IsoRay First Quarter Fiscal 2020 Call. All lines have been placed in a listen-only mode and the floor will be open for your questions and comments following the presentation. At this ti ...
Perspective Therapeutics(CATX) - 2019 Q4 - Annual Report
2019-09-27 21:13
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File No. 001-33407 Isoray, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |---------------- ...